Neuromodulation, or the utilization of advanced technology for targeted electrical or chemical neuronal stimulation or inhibition, has been expanding in several neurological subspecialties. In the past decades, immune-modulating therapy has been the main focus of multiple sclerosis (MS) research with little attention to neuromodulation. However, with the recent advances in disease-modifying therapies, it is time to shift the focus of MS research to neuromodulation and restoration of function as with other neurological subspecialties. Preliminary research supports the value of intrathecal baclofen pump and functional electrical stimulation in improving spasticity and motor function in MS patients. Deep brain stimulation can improve MS-related tremor and trigeminal neuralgia. Spinal cord stimulation has been shown to be effective against MS-related pain and bladder dysfunction. Bladder overactivity also responds to sacral neuromodulation and posterior tibial nerve stimulation. Despite limited data in MS, transcranial magnetic stimulation and brain-computer interface are promising neuromodulatory techniques for symptom mitigation and neurorehabilitation of MS patients. In this review, we provide an overview of the available neuromodulatory techniques and the evidence for their use in MS.
Introduction
Neuromodulation, or the utilization of advanced technology for targeted electrical or chemical neuronal stimulation or inhibition, has been expanding in several neurological subspecialties. Movement disorders and post-stroke pain syndrome are among the most common neurological indications for neuromodulation at the present time. In multiple sclerosis (MS), intrathecal baclofen (ITB) pump has been the main neuromodulation technique utilized by many patients for advanced spasticity management. In addition to ITB, several other neuromodulation options are available for symptomatic management and functional optimization of MS patients; however, they are yet to be utilized on a large scale. In this article, we will provide an overview of the different neuromodulation applications in MS. These applications include ITB pump, functional electrical stimulation, deep brain stimulation, transcranial magnetic stimulation, bladder stimulation, spinal cord stimulation, and brain-computer interface (see Figure 1 ).
ITB pump
Although mild to moderate MS-related spasticity can be managed by oral anti-spasticity agents, advanced spasticity may be refractory to the maximum tolerable doses of these medications and may therefore require specialized management. 1 While botulinum toxin is the preferred treatment for focal spasticity, ITB via an implanted subcutaneous pump is the preferred option for diffuse spasticity. 1 The ITB pump is surgically implanted in the abdominal subcutaneous tissue and is connected to a catheter ending in the thoracic intrathecal space. 2 The pump provides a continuous basal rate of ITB at concentrations much smaller than those given orally and allows for additional boluses as needed. The continuous intrathecal infusion of baclofen provides more effective antispasticity effect below and, to a lesser extent, above the level of the catheter tip compared to oral baclofen. 3 In a survey by the North American Research Committee on Multiple Sclerosis (NARCOMS) published in 2004, 84% of patients reported some symptoms of spasticity but only 1% had an implanted ITB pump. 3 Given the fact that about 13% of MS patient were estimated to be potential candidates for ITB, 3 this effective treatment modality may be underutilized in MS.
The patient selection process in MS follows the same general principles for other ITB indications with severe diffuse spasticity, intractable tonic spasms, and inadequate response or poor tolerability to oral agents being the most common. 4 Patients must exhibit a good response to a test dose of ITB prior to implantation as demonstrated by objective improvement in the modified Ashworth spasticity scale (MASS) by at least one point, subjective sense of improvement, and absence of impactful ITB-induced weakness.
ITB pump was found to be effective in reducing both tonic spasticity (as represented by the MASS) and phasic spasticity (as represented by reduction of spasm frequency in MS patients). 5 In non-ambulatory MS patients, ITB has been shown to provide relief of discomfort and pain related to spasticity, greater ease of care, improved posture, and improved ability to transfer. 5 Although more widely utilized in non-ambulatory patients, ITB improved spasticity without causing increased weakness in a study of 36 ambulatory MS patients up to 3 years from implantation. 6 A survey of 198 MS patients using ITB found significantly lower levels of spasticity compared to a group of 315 patients using oral medications. 3 ITB patients also reported a higher level of satisfaction with the results of treatment compared to patients on oral therapy. In addition, ITB has been shown to significantly improve sleep quality in patients with MS without adverse effect on respiratory function. 7 It has also been linked to improved pain and depression in MS patients. 8 Improvement of bladder function has also been reported in older studies, 9 but this has not been a primary focus of more recent studies probably due to the availability of other effective neuromodulatory techniques for overactive bladder as will be discussed later in this review. Despite previous concerns, ITB seems to be safe with pregnancy in the young population of MS patients. 10 Repeated magnetic resonance imagings (MRIs) do not seem to cause significant adverse events in MS patients with ITB pumps. 11 MRI will cause the ITB pump to stall but spontaneous recovery often follows. Pump interrogation after MRI is recommended to ensure resumption of normal functioning and rule out protracted motor stall. 11 Most MRI experience with ITB pumps is restricted to one or two specific models so it is advisable to always contact the manufacturer for instructions prior to MRI especially in patients with old or infrequently used pump models.
Side effects and complications from ITB therapy in MS do not generally differ from those reported in other populations, with surgical complications, hardware infection, and catheter malfunction being the most common. 12, 13 MS is associated with a higher prevalence of seizures than the general population, 14 therefore increased seizure risk is a possible concern. A retrospective review of 99 MS patients treated with ITB found a higher incidence of seizures compared to a comparison group without ITB (7% vs 1%), although the seizures in the ITB group were often associated with other potential triggers. 15 Baclofen withdrawal is a rare life-threatening complication of ITB therapy that manifests with worsened spasticity, tonic spasms, seizures, itching, and other features of central nervous system (CNS) overstimulation. It can result from missed or inappropriate pump refill, or rarely, from programming errors or baclofen leakage. 16 Overall, the benefits of ITB pump in MS patients with advanced diffuse spasticity likely outweigh the risks when cases are properly selected and managed in specialized centers. Consistent with the advice of spasticity experts in several recent articles, 1,17 larger scale and earlier utilization of this technique is recommended.
Functional electrical stimulation
The use of peripherally applied functional electrical stimulation (FES) in the neurorehabilitation of MS patients is a promising method for optimization of function. FES is applied peripherally to the nerve supply of weak muscles (e.g. foot extensors) to restore function and prevent muscle atrophy. FES devices range from small stimulation units, to wearable orthotics that can be used for the long-term management of foot drop and/or finger weakness, and to FES-based stationary bikes that can be used at home or in outpatient rehab centers. 18 More recently, implantable forms of FES devices have been developed as an alternative to conventional transcutaneous stimulation providing similar efficacy and improved convenience. 19, 20 Implantable FES devices can also be used for restoration of upper extremity function. 21 A common example of FES utilization in MS patients is stimulation of the common peroneal nerve (CPN) in patients with foot drop. The daily use of a wearable FES device for 2 weeks in 19 MS patients with foot drop resulted in significant short-term improvement in walking speed and patient-reported outcomes. 22 In a separate study, walking speed and distance-but not patient-reported outcomes-improved in nine MS patients with foot drop over the course of 12 weeks of FES therapy. 23 The positive effect on walking speed was supported in a large number (153) of real-life MS users of CPN FES after 20 weeks of use with an average improvement of 27%. 24 Wearable FES was also studied in combination with dalfampridine in MS patients with slowed walking and foot drop. It was shown to significantly improve walking speed, quality of life (QOL), and patientreported outcomes after 3 months of daily use compared to dalfampridine alone. 25 There was no report of increased tonic spasms as a result of the FESdalfampridine combination.
FES can reduce falls in MS patients 26 and may have a beneficial effect on spasticity based on studies in poststroke patients (although data regarding the latter effect is variable). 27, 28 The literature on the comparative use of FES devices for foot drop versus conventional ankle-foot orthotics (AFO) is scarce, especially in MS patients. The available literature from stroke and MS studies suggest comparable effect of both methods but with slight increase in stability with AFO and better physical activity and obstacle avoidance with FES. [29] [30] [31] [32] The choice between the two modalities should be based on patient preferences and economic considerations.
Several studies analyzed the therapeutic effects of FES and regular physical therapy (PT)/exercise programsin conjunction and alone-in MS patients. In a study of 44 patients with secondary progressive multiple sclerosis (SPMS) and unilateral foot drop, significant improvement of walking speed and distance walked in 3 minutes were observed in patients undergoing 18 weeks of non-FES home exercise program but not in patients undergoing daily FES of the CPN through a wearable device. 33 However, within the FES group, significant improvement in walking speed and distance were observed with FES-on compared to FES-off. On the contrary, Taylor et al. 34 found that the combination of FES and exercise is better than exercise alone in improving walking speed and patient-reported outcomes in MS patients with foot drop. As part of a restorative activity-based therapy, FES-based cycling led to stabilization or improvement of Expanded Disability Status Scale (EDSS) in 75% of patients with primary progressive multiple sclerosis (PPMS) with a 9% average improvement. Similar, but less robust, results were also found in patients with relapsing-remitting multiple sclerosis (RRMS) and SPMS. 35 Those results suggest a long-lasting effect of FES on functional recovery beyond simple mechanical correction of a lost function. The exact mechanism by which FES exerts such an effect is unknown, but is thought to modulate neuroplasticity and enhance progenitor cell birth leading to remyelination and axonal growth as shown in experimental animal models. 36, 37 It is worth noting that this long-term therapeutic effect of FES-based cycling was not observed in all studies. 38 In summary, peripherally applied FES via wearable devices or exercise machines may provide both mechanical and biological benefits to MS patients. It should be utilized more often in MS research and routine care, especially because demyelinated central fibers could hypothetically be more responsive to trans-synaptic modulation through electrical stimulation compared to the infarcted or transected fibers found in patients with stroke or spinal cord injury (SCI).
Deep bran stimulation
Deep brain stimulation (DBS) is an advanced surgical technique that involves implantation of stimulation electrodes in one or more deep nuclei of the brain. 39 Implanted via a stereotactic approach, the stimulation electrode provides electrical stimulation at the target nucleus that is functionally equivalent to lesional surgery. 40 The electrode is connected via a tunneled extension wire to an intermittent pulse generator (IPG) that is implanted subcutaneously below the clavicle. DBS has become the standard of care for medically refractory cases of essential tremor (ET), Parkinson's disease (PD), and primary generalized dystonia, nearly replacing the older techniques of thalamotomy and pallidotomy. 39 Unlike lesional surgery, DBS is reversible and can be programmed to mitigate side effects and cope with disease progression. The utilization of this effective technique in MS has been very limited compared to movement and psychiatric disorders with MS tremor being the most targeted symptom. 41 MS can cause postural and/or intentional tremor. 42 In many cases, MS tremor is accompanied by cerebellar ataxia. The prevalence of clinically detectable tremor in MS ranges from 26% to 58% depending on the population studied with disabling tremor present in 3%-27% in these populations. 43, 44 In addition to being one of the most disabling MS symptoms, it is also the most resistant to treatment. 42 Surgical options for medically refractory MS tremor include stereotactic thalamotomy, radiosurgery, and DBS. 42 Inspired by the surgical target for ET, most DBS studies in MS have targeted the ventral intermediate nucleus (VIM) of the thalamus. 41 Although a small number of MS patients have commonly been included in most DBS studies for resistant tremor of variable etiologies, a few studies have focused mainly or largely on MS tremor. [45] [46] [47] [48] [49] [50] The average number of MS patients studied ranged from 9 to 15, and the great majority were implanted unilaterally at the brain side opposite to their most affected upper extremity. Tremor reduction was seen in 69%-100% of patients across studies but functional improvement was less consistent, ranging from 0% (in several studies) to 92% (in one study). 45 In addition to this limited functional impact, the traditional unilateral VIM approach had several other limitations including lack of effect on proximal tremor and loss of benefit over time. These limitations may be related to the complexity of MS tremors, which have both cerebellar and pallidal components and commonly overlap with ataxia. 51 Due to the limitations of the traditional unilateral VIM approach, many researchers have experimented with different surgical targets and approaches to improve MS tremor. Whittle et al. 52 targeted the ventralis lateralis (VL) nucleus bilaterally in four patients with bilateral MS tremor yielding excellent improvement in both tremor control and functional status in all four patients. Nandi and Aziz 53 reported positive objective improvement in proximal MS tremor after lead placement unilaterally or bilaterally in the zona incerta (ZI) and the ventralis oralis posterior (VOP) nucleus of the thalamus (the surgical trajectory placed the distal contacts of the lead in the ZI and the proximal contacts of the same lead in the VOP).
Working with the same research group, Bittar et al. 54 compared thalamotomy to unilateral thalamic DBS (VOP for distal, ZI for proximal, and ZI/VOP straddling lead for mixed MS tremor) in a non-randomized, nonblinded study. There was no statistically significant difference in postural tremor control between the two techniques. However, thalamotomy was significantly more effective against intentional tremor. More complications were observed with thalamotomy than with DBS, thereby leading the authors to recommend the latter as the preferred surgical technique for MS tremor.
More recently, Oliveria et al. 51 reported a singleblinded randomized pilot trial of unilateral dual lead thalamic DBS for MS tremor. They included 12 patients with RRMS or PPMS in whom they implanted one lead in the VIM and a separate lead in the ipsilateral ventralis oralis (VO) nucleus at the junction between the VOP and the ventralis oralis anterior (VOA). The study met its primary outcome with significant tremor improvement at 6 months post implantation with both leads on. In addition to common DBS complications (e.g. cranial bleeding, off-target stimulation, hardware migration/ malfunction), MS patients may be especially susceptible to specific adverse events related to DBS implantation. Seizures have been frequently reported as an adverse event following DBS implantation in MS patients. 42 Likewise, the fact that many MS patients receive long-term immunomodulating therapy raises concerns about increased susceptibility to hardware and wound infection after DBS surgery. Reported adverse events in previous studies support these concerns. 45, 47, 49 However, it should be noted that the rates of seizures and infections have not been compared to other DBS populations. In addition, most of the studies that reported high infection rates post-DBS predate modern disease-modifying therapy (DMT) when many MS patients were treated with more conventional immunosuppressive agents and periodic steroids. Several studies also reported new MS relapses following DBS surgery. Some authors elected to preoperatively treat MS patients with high-dose intravenous (IV) steroids, 54 but the value of such intervention is unknown and is not widely popular in modern clinical practice.
In summary, DBS may be a beneficial technique to reduce MS tremor although exploration of new targets is needed to bridge the gap between tremor reduction and actual functional improvement. The VL, VOP, and ZI are potential surgical targets instead of-or in addition to-the more traditional VIM. Proper case selection is essential for better future outcomes. Patients with distal postural tremor who have no significant ataxia, spasticity, or sensory deprivation in the tremulous limb seem to experience better outcomes from DBS. 41 The recent advent of DBS systems compatible with fullbody MRI is expected to increase the utilization of DBS for MS tremor and possibly for other indications like TN, chronic pain, and bladder dysfunction.
Transcranial magnetic stimulation (TMS)
TMS is a noninvasive tool that can be used for neuromodulation in a number of different conditions. It has mainly been used in the treatment of neuropathic pain, major depression, and complications related to stroke and SCI. 57, 58 Past research has suggested that TMS may alter neuronal activity by a number of different mechanisms. Some of the proposed mechanisms involve inducing long-term depression, causing long-term potentiation, shifting network excitability, changing activity-dependent metaplasticity, and activating feedback loops. 59, 60 Multiple studies have found that repetitive transcranial magnetic stimulation (rTMS) can reduce spasticity in MS patients.
A 2-week protocol of repeated 5-Hz rTMS to the primary cortex of patients with RRMS improved lower limb spasticity up to 1 week. 61 Mori et al. 62 found similar results using intermittent theta burst stimulation (iTBS) with benefits on lower limb spasticity up to 2 weeks after stimulation. A study investigating the use of iTBS and exercise therapy to improve motor disability in RRMS patients found that 2 weeks of both treatments induced a greater reduction of spasticity and fatigue than either treatment alone. 63 It is thought that iTBS may play a role in priming the motor cortex for the neuronal activity underlying the therapeutic action of exercise therapy.
In one controlled study, the application of 5-Hz rTMS to the motor cortex of eight MS patients with cerebellar dysmetria resulted in improved hand dexterity as evidenced by enhanced ability to complete the ninepeg-hole test with the affected limb. However, the improvements were short-lasting and were lost by 20 minutes after stimulation. 64 A similar study found that patients exhibited improved hand dexterity for up to 1 month after stimulation. 65 Centonze et al. 66 found that rTMS therapy over the course of 2 weeks may improve lower urinary tract symptoms with objective improvement of the voiding phase.
Although generally safe, it has been shown that TMS may increase the risk of seizures in patients with MS. 67 Therefore, it should be avoided in patients with a known history of seizures. It should also be used with caution in patients with visible cortical or large juxtacortical lesions.
In summary, rTMS may be useful for some MS symptoms, particularly muscle and bladder spasticity. There is, however, a limited amount of research and an absence of replicated controlled studies concerned with this topic. More research is needed before TMS can be recommended for the routine clinical care of MS patients.
Spinal cord stimulation (SCS)
SCS involves lead placement over the central part of the epidural space to stimulate the dorsal columns and block pain signals. 68 As in ITB pump, patients considered for SCS must demonstrate a meaningful improvement in the target symptom (usually pain) during a period of test stimulation before the electrodes are internalized for long-term use. 68 Percutaneous leads can be implanted via minimally invasive surgery, while the more traditional paddle leads are surgically implanted via a laminotomy. The leads are connected to an IPG that is implanted subcutaneously usually in the lower back.
The exact mechanism of action of SCS is unknown. Proposed mechanisms of action include changing nerve conduction properties, changing excitatory states, modifying functional and anatomical organization, and/or altering neurotransmitter release. 69 The common final pathway of these proposed mechanisms is based on masking pain signals proceeding from the dorsal roots via stimulation of the dorsal columns (the gate control theory). 70 SCS may also promote the differentiation of oligodendrocyte precursor cells, the primary remyelinating cells in the CNS. 71 SCS is US Food and Drug Administration (FDA)approved for treatment of chronic trunk and limb pain secondary to conditions like failed-back syndrome, complex regional pain syndrome (CRPS), and lumbar radiculopathy. 72 The literature on the use of SCS in MS is scarce, and most studies are several decades old. MS patients usually comprised a subset of the subjects of any given study, but a few studies specifically focused on MS. Illis and colleagues reported some of the earliest work on SCS in MS. Their small, studied cohort reported improvement in subjective motor, sensory, and bladder function. 69, 73, 74 The most robust improvement was observed in bladder function (75%), while the quantitative effects on objective motor scales were limited. Similarity, Cook et al. [75] [76] [77] [78] reported that MS patients treated with SCS experienced improved motor, sensory, bladder, and even cerebellar functions. Abbate et al. 79 specifically investigated the effects of dorsal SCS on bladder dysfunction in MS patients. Of the 40 patients studied, 77% noted a subjective improvement in bladder function. Objective improvements (e.g. increased bladder capacity, improved sphincter control, and increased continence) were noted in 42.5% of the patients, as demonstrated by cystometry and sphincter electromyography (EMG). Hawkes et al. 80 found that SCS delivered over the course of a 2-week period to a group of 19 MS patients caused 8 patients to increase walking speed, 7 patients to improve hip flexor strength, and 2 to increase grip power; however, these results were thought to have been confounded by motor learning from repeated practice. 80 A separate study found that spasticity and tonic spasms in MS patients may be markedly reduced in response to SCS. 81 Contrary to these early positive reports, Rosen and Barsoum 82 found no objective benefit of SCS in nine MS patients over a period of 37 months. Likewise, Young and Goodman 83 reported lack of significant improvement in motor, sensory, or bladder functions in 23 MS patients followed over a 32-month period.
Given the debatable effect of SCS on motor functions in MS, most subsequent studies focused on more conventional outcomes related to pain control. One of the largest longitudinal cohorts is the one reported by Kumar et al. [84] [85] [86] Of the 410 total patients reported in their 2006 paper, 19 MS patients with chronic lower extremity pain were trialed and 17 were implanted. Over an average follow-up of 97 months, 74.1% of the entire cohort retained significant pain improvement after implantation.
For the past decade, many of the studies investigating the effect that SCS has on MS-related pain have been case reports or miniseries. Burkey and Abla-Yao 87 presented a case report of a woman with MS whose hand pain was relieved with SCS but not with medications, sympathetic blocks, or acupuncture. Provenzano et al. 88 presented a case report of a man with MS-related neuropathic lower extremity pain whose pain was so markedly reduced with SCS that he was able to reduce his opioid consumption by more than 99%. In a miniseries of eight patients with thalamic pain syndrome, a total of six patients experienced long-term pain relief after SCS (including 1 of 2 MS patients). 89 As in DBS, one problem that hinders the widespread utilization of SCS in MS patients is the need for frequent MRIs to monitor disease activity. Magnetic fields can cause heating of the stimulator hardware; this can result in patient injury and/or permanent system malfunction. 90 In general, MRIs are indicated in patients with SCS only when the benefits outweigh the risks and when strict precautions are followed. Most SCS systems are compatible with brain MRI provided that the brain MRI is performed with a 1.5-T closed magnetic field and has predefined technical limitations to the coil type, spatial gradient, radiofrequency, and absorption rate. One SCS manufacturer received FDA approval for whole body MRI under two conditions: the given studies lasted no longer than 30 minutes and had technical limitations similar to those found with brain MRI. 91 In all cases, the stimulator system has to be interrogated prior to MRI use to ensure the absence of lead breaks and short circuits that might increase the risk of overheating. The stimulator system must be turned off prior to the initiation of a given study; it must be turned back on afterwards with repeat interrogation.
Other difficulties related to the use of SCS include hardware infection, lead displacement, lead breaks, and the frequent need for corrective procedures. 80, 83 These complications were estimated to affect 65% of MS patients in one study. 83 In summary, SCS may have a positive therapeutic effect on refractory neuropathic pain and bladder dysfunction in MS patients. Its effects on motor function are debatable and require more research. The effect on spasticity is promising, and the recent literature calls for further research on this topic. 92 
Bladder stimulation
In the past, neuromodulatory treatment of overactive bladder has involved intravesical, anal, vaginal, penile, and perineal electrical stimulation; these techniques proved to be inconvenient and ineffective. 93 The results of other studies, however, have suggested that the use of sacral neuromodulation (SNM) and posterior tibial nerve stimulation (PTNS) may be therapeutically beneficial for MS patients suffering from overactive bladder.
SNM involves stimulating the pelvic nerves, but its exact mechanism of action is unknown. SNM may potentiate the somatic afferent inhibition of sensory processing of the bladder in the spinal cord, or it may directly inhibit efferent input to the bladder. 94 While acute percutaneous stimulation of the pelvic nerves, particularly S3, has been shown to have some therapeutic benefit to MS patients with bladder overactivity, the technique is impractical. 95 The implantation of a device that stimulates the pelvic nerves is a preferred technique. 94 Minardi and Muzzonigro 96 found that SNM via an implantable IPG improved the urinary symptoms in 25 MS patients who suffered from medication-refractory overactive bladder and responded positively to test stimulations of the sacral nerve. Similarly, Marinkovic and Gillen 97 found that 12 female MS patients with bladder hyperactivity who underwent successful SNM IPG implantation experienced a decreased number of catheterizations per day. In a retrospective study of 17 MS patients utilizing SNM outside of trial setting, 75% of patients reported significant and long-lasting effect on QOL, bladder symptoms, and number of self-catheterizations. Results were favorable in patients who had either storage or voiding symptoms, but not in those with mixed symptoms. 98 While the use of implantable SNM for treatment of bladder hyperactivity in MS patients is promising, there have been some side effects including stimulation-related pain and hardware malfunction. 96, 97 PTNS has also been demonstrated to be effective in the treatment of overactive bladder. PTNS involves stimulating the posterior tibial nerve, which contains L4-S3 fibers. Although the mechanism of action remains unproven, Caldwell 99 suggests that electrical stimulation of the tibial nerve may inhibit bladder activity by depolarizing somatic sacral and lumbar afferent fibers.
These depolarized fibers, in turn, inhibit preganglionic bladder motor neurons in the spinal cord. 100 Kabay et al. 101 found that percutaneous PTNS (needle piercing the skin behind the medial malleolus) over 12 weeks improved urodynamic measurements in 19 MS patients with overactive bladder. Results showed increased mean urine volume, increased maximal cystometric capacity, and suppressed detrusor contraction. In addition, percutaneous PTNS has been shown to improve subjective lower urinary tract symptoms in MS patients. 102 The use of transcutaneous (via surface electrodes) PTNS, rather than percutaneous PTNS, may also be therapeutically effective in treating MS patients with overactive bladder. It is less invasive. Using a sample size of 70 patients, a study found that daily 20-minute transcutaneous PTNS sessions over the course of 3 months resulted in reduced urinary urgency, frequency, and incontinence. 93 The effects were short-lasting, but persisted for the entire day after each treatment.
To the best of our knowledge, the transcutaneous technique has not been studied against the percutaneous technique in bladder dysfunction. However, based on fecal incontinence studies, the percutaneous technique is thought to be relatively more effective. 103 Also based on fecal incontinence non-randomized studies, SNM and PTNS are thought to be comparable in efficacy. 104 PTNS is more cost-effective than SNM for bladder overactivity, but patients utilizing SNM are less likely to discontinue therapy. 105 In conclusion, the results of recent studies suggest that SNM and PTNS may be helpful in the neuromodulation of MS-related overactive bladder. These techniques may not only decrease the severity of symptoms but also significantly improve the QOL. 93, 96, 102 Because most of the data are limited to case studies, however, these techniques are currently not included in expert panel consensus recommendations in some countries. 106 SNM and PTNS are not recommended for MS patients with bladder hypoactivity. 96
Brain-computer interface and neurobionics
Brain-computer interface (BCI) systems aim to connect brain cells to external electronic devices to compensate for lost neurological functions. 107 BCIs can be motor or sensory. In a motor BCI, electrical fields from brain cells are collected via intracortical or surface electrodes, amplified, and then connected to a robotic prosthesis or an implanted electrode in a paralyzed limb to regain motor function. BCI connected to a body exoskeleton has been successfully used to restore ambulation in paraplegic patients. 108 Our center and others have successfully used BCI to restore upper extremity functions. 109, 110 In a sensory BCI, intact brain cells are used as receptors to electrical signals from external devices to restore a lost sensory function like tactile sensation, hearing, or vision. [111] [112] [113] Less-complex neurobionics that do not rely on cortical electrical fields include peripherally activated neuro-prosthetics operated by visual tracking systems or residual myoelectrical activity in partially paralyzed patients. 114, 115 Combining both cortical and peripheral activation can enhance restoration of function and improve precision in patients with neurological deficits. 109 The majority of BCI and neurobionic applications have been tested in patients with traumatic injury to the CNS, particularly the spinal cord. 116, 117 To date, the utilization of this technology in MS patients has been limited both clinically and experimentally. The success of BCI technology in patients with SCI relied on the presence of intact brain cells and the non-progressive nature of their condition. The situation is clearly different in patients with MS who commonly suffer from both brain and cord diseases, and who invariably follow a relapsing and/or a progressive course. 118 The widespread application of BCI in MS patients will require adaptive technology that can be adjusted to disease progression and change of function over time.
MS patients receiving immunomodulating therapy can be more prone to hardware infection and periimplantation complications. MRI compatibility of the BCI system is another problem unique to MS patients who require regular MRI monitoring. However, the demyelinating pathology may be an advantage for MS patients over the complete neural/axonal transection commonly present in SCI patients. As opposed to neuronal or axonal loss, demyelinating lesions often result in partial loss of function, leaving enough residual activity to operate peripherally controlled neurobionics. 119, 120 Demyelinating lesions also retain the ability to transmit neural signals to some degree. Therefore, in a manner similar to FES-based therapy described earlier in this review, they may be more amenable to enhancement of function and neural recovery in response to long-term BCI-based or neurobionicsbased neurorehabilitation. 121 To date, the limited use of BCI technology in MS patients included a study of a BCI-based web browser in 16 severely disabled MS patients. The BCI was operated by the patients' visual evoked potentials, and it resulted in 84% web-surfing accuracy compared to 95% accuracy in healthy controls. 122 In a study of multimodal neuroprosthesis for optimization of upper limb function in severely disabled patients, two MS subjects with residual upper limb function were fitted to an external arm prosthetic operated by residual myoelectrical potentials (EMG waves) and successfully performed prosthetic-assisted drinking and reaching tasks. 120 However, one of the two patients reported more exhaustion when using the exo-prosthetic than when using her own arm.
BCI and neurobionics technologies are promising for patients with MS and other demyelinating diseases for both restoration of function and neurorehabilitation. Unfortunately, the body of the literature is very limited to date. More research is needed to explore the possible therapeutic benefits that these technologies may have for MS patients.
Conclusion
With the recent advances in immunomodulation therapies for MS, it is time to shift the focus of MS research to neuromodulation and restoration of function as with other neurological subspecialties. Several neuromodulatory techniques have shown preliminary value in various aspects of the disease process, but more research is greatly needed to advance this field. See Table 1 for a summary of the potential target symptoms for neuromodulation in MS.
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